At medical spas that have been running a GLP-1 program for at least six months, semaglutide and tirzepatide services now contribute approximately 15% of total monthly revenue, according to Guidepoint Qsight market analysis published in January 2025. Early-stage programs, fewer than 25 active patients, land between 4 and 10%. Programs past 60 patients that have optimized their bundle hit 20 to 28%. Knowing where you sit on that range tells you where to allocate staff and where the next margin point comes from.
Most owners who start a GLP-1 program treat it as a side service that runs itself. They put a patient on semaglutide, collect a monthly fee, and move on. The program has a distinct financial structure from every other service in the building. It is a recurring revenue model inside what is otherwise a per-visit business. That changes how you evaluate profitability and how you track it in your books. None of that happens automatically. You have to build the financial view on purpose.
Below is what the 15% number means, how to calculate your own contribution, and how GLP-1 margins compare to your injectable service line.
What Counts as a GLP-1 Program at a Medical Spa?
A GLP-1 program at a medical spa includes all revenue generated from weight management services that involve a GLP-1 receptor agonist medication, whether compounded or branded. The program definition matters for accounting because you need to draw a clean line around what goes in and what stays out.
Revenue that belongs in the GLP-1 program line: the initial consultation fee, monthly medication supply charges, monthly follow-up visit fees, body composition monitoring appointments, lab work billed through the practice, and any nutrition or lifestyle coaching that is bundled into the program tier. If a patient pays $400 per month for a program that includes medication plus monthly monitoring, the full $400 goes to GLP-1 program revenue.
Revenue that does not belong in the GLP-1 program line: IV therapy upsells that are not part of the program bundle, aesthetic services the patient also receives, vitamin injections billed as standalone visits, or any ancillary service the patient buys independently of the weight management program. Letting these blur the line inflates your apparent GLP-1 contribution and hides what the program actually produces on its own.
Compounded and branded GLP-1 programs have different margin structures. Compounded programs carry higher gross margins because the drug cost is lower. Branded programs at cash-pay pricing for Ozempic, Wegovy, or Mounjaro carry lower margins. The Guidepoint Qsight benchmark covers both. Your margin depends entirely on which sourcing model you run.
GLP-1 Program Revenue by Maturity Stage
The 15% benchmark reflects a functioning program, not a starting point. The table below shows how contribution builds over time, using the $200 to $500 per month patient pricing range and the Guidepoint Qsight benchmark as anchors. Patient counts and revenue figures use $250 as the floor of that pricing band.
| Program Stage | Active Patients | Illustrative Monthly GLP-1 Revenue | Approx. % of Practice Revenue | What Drives the Stage |
|---|---|---|---|---|
| Early (0–6 months) | 10–25 patients | $2,500–$8,750 | 4–10% | Word-of-mouth only, no dedicated marketing |
| Established (6–18 months) | 25–55 patients | $8,750–$19,250 | 10–18% | Referral engine working, program pricing optimized |
| Optimized (18+ months) | 55–100+ patients | $19,250–$35,000+ | 18–28% | Dedicated NP or PA, tiered program pricing, strong retention |
Revenue figures use $250 per patient per month as the floor of the pricing range. Practices charging $350 or higher will earn more at the same patient counts. The percentage column assumes a practice doing $80,000 to $100,000 per month in total revenue, consistent with the practices in the Guidepoint Qsight data. If your practice runs higher or lower, adjust the percentage.
How to Calculate Your GLP-1 Program Revenue Contribution
The benchmark only works if you can calculate your own number. Most practices cannot do this on day one because GLP-1 revenue is mixed into general treatment revenue or injectable revenue in QuickBooks. Before you can benchmark, you need a clean line.
- Isolate GLP-1 service revenue in your POS. Pull a service revenue report filtered to all GLP-1 or weight management service codes for the period you are measuring. If your POS does not have a dedicated code, create one before the next billing cycle. Do not estimate this number by memory.
- Add initial consultation fees. If you charge a separate consult fee at program enrollment, that belongs in the GLP-1 revenue total. Pull it out of your general consult revenue and add it to the program line for the months where new enrollments occurred.
- Add monthly follow-up and monitoring visit revenue. Any recurring monthly office visit billed as part of the program, whether it is a 15-minute check-in or a full body composition assessment, counts. If these visits are bundled into the monthly fee, they are already captured in step one. If they are billed separately, add them here.
- Add ancillary charges that are part of the program bundle. Labs, B12 injections that are part of the weight management protocol, and nutrition coaching fees that are included in the program tier all belong on the GLP-1 revenue line. Standalone services the patient also happens to buy do not.
- Subtract all direct program COGS. This includes medication cost from your compounding pharmacy or branded supplier, injection supplies, any per-patient lab costs billed to the practice, and a fair allocation of physician or nurse practitioner oversight time if that cost is dedicated to the program. This step is where most practices fall apart. They track revenue but not cost, so they never see the real margin.
- Divide net program contribution by total practice revenue. The result is your GLP-1 program contribution percentage. Compare it to the 15% benchmark. If you are below 10% with more than 25 active patients, pricing or retention is the problem. If you are below 10% with fewer than 25 patients, the program is still in the early phase and the benchmark does not yet apply.
Sample Calculation: 40-Patient Program
A 40-patient program at $325 per month average spend, middle of the observed pricing range. COGS modeled at 38% covers drug cost, supplies, and part-time NP oversight. Total practice revenue assumed at $80,000 per month.
At 16.3% of practice revenue, this program sits above the Guidepoint Qsight benchmark. Net contribution after COGS is $8,060 per month. Each patient contributes $201 per month in gross margin. That $201 tells you whether adding the 41st patient is worth the overhead, and it is the number that disappears when GLP-1 revenue is not tracked separately.
GLP-1 Margins vs. Your Injectable Service Line
GLP-1 margins and injectable margins are not the same structure. Comparing them the wrong way leads to bad staffing and marketing calls. The cost side is different. The revenue model is different.
Injectables run 60 to 70% gross margin after Allergan, Galderma, Merz, and Evolus product costs are reconciled against service revenue. The real injectable margin, once vendor invoices are subtracted, is not the 80% or higher that appears in QuickBooks when product costs are missing from the books. GLP-1 programs have a different cost profile because the drug cost is a larger portion of the patient payment than neurotoxin or filler cost is of an injectable appointment.
| Service Line | Revenue Model | Typical Gross Margin | Primary COGS Driver | Revenue Predictability |
|---|---|---|---|---|
| GLP-1 program (compounded) | Recurring monthly | Varies by drug cost | Medication + MD/NP oversight | High: monthly subscription |
| Neurotoxin (Botox/Dysport) | Per visit, 3–4x/year | 60–70% | Toxin units at vendor pricing | Medium: seasonal variation |
| Dermal filler | Per visit, 1–2x/year | 60–70% | Filler syringe cost at vendor pricing | Low: infrequent repeat cycle |
| Laser / energy device | Per session or package | High after device payoff | Consumables only post-breakeven | Medium: package sales |
Every injectable appointment has to be re-earned. A patient on a GLP-1 program pays monthly until they reach their goal or decide to stop. That recurring structure changes how you model revenue and how you think about retention investment. A practice with 60 GLP-1 patients has $15,000 to $21,000 in predictable monthly revenue in its base before a single injectable appointment is booked. That is a different business than one where every dollar depends on who calls in this week.
The Recurring Revenue Advantage
The financial case for GLP-1 is the compounding effect of retaining patients month over month. A patient who pays $325 per month for 12 months generates $3,900 from one acquisition. A Botox patient coming in every four months at $600 per visit generates $1,800 over the same period, requires re-booking three times, and needs re-activation if they lapse.
Practices in the optimized stage have built the program into their operational model. They have a dedicated provider for weight management and a retention protocol for patients considering stopping. The patient communication runs on a schedule. The financial result shows up as higher GLP-1 contribution percentage and lower patient acquisition cost per dollar of revenue, because each acquisition yields more lifetime value.
A practice with high GLP-1 churn, patients stopping after two or three months, will never reach the benchmark no matter how many new enrollments it generates. Churn is the biggest leak in a recurring revenue model. If your program is below benchmark with more than 25 active patients, check your three-month and six-month retention rates before touching pricing or marketing.
Any GLP-1 program financial model built on compounded semaglutide pricing needs a brand-switch scenario. The FDA removed semaglutide from its drug shortage list for branded products in early 2025, which complicates the legal basis for compounding. Availability can change on short notice depending on FDA enforcement posture and state pharmacy board rules.
If your program transitions from compounded to branded pricing, your COGS structure changes substantially. Model both scenarios in your program P&L before you need to make the switch under pressure. Verify current compounding status with your pharmacy and legal counsel before each prescription renewal cycle.
How to Track GLP-1 Revenue Correctly in QuickBooks
The benchmark only works if your books capture GLP-1 revenue and COGS separately from the rest of the practice. Most practices that have been running a program for a year cannot tell you their actual GLP-1 gross margin because the revenue is mixed into general service revenue and the drug costs are coded to medical supplies or office expenses. That makes it impossible to benchmark the program or make a sound decision about whether to grow it.
The setup in QuickBooks has three pieces. First, a dedicated income account for GLP-1 program revenue, separate from injectable revenue and aesthetic treatment revenue. A label like 4400 Weight Management Revenue or 4410 GLP-1 Program Revenue works. Second, a dedicated COGS account that captures medication costs, supplies, and any direct labor associated with running the program, such as contracted NP or physician oversight fees. A label like 5400 Weight Management COGS or 5410 GLP-1 Drug Cost works. Third, all GLP-1 service items in your POS map to the income account, and all compounding pharmacy invoices map to the COGS account, not to medical supplies.
Once that is set up, your QuickBooks P&L shows a GLP-1 gross margin line. Run it monthly. Compare it to your injectable gross margin line. Watch whether the program is improving or deteriorating. Without it, you are flying the program without instruments, which is how practices end up running a GLP-1 service at a loss for a year before realizing it.
Spa Ledger tracks your GLP-1 program P&L separately from injectables every week
We set up the QuickBooks structure, reconcile your compounding pharmacy invoices against program revenue, and deliver a weekly dashboard that shows gross margin by service line, including GLP-1. You always know whether the program is pulling its weight.
Get Started